Amgen Inc

AMGN

276.390USD

-6.340-2.24%

Close 09/12, 16:00（ET）Quotes delayed by 15 min

Score

Industry at a Glance

Industry Ranking

34 / 176

Overall Ranking

137 / 4724

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 34 analysts

Buy

Current Rating

313.494

Target Price

+13.42%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 26.98% year-on-year.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 120.56%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 120.56%.

Fairly Valued

The company’s latest PE is 22.44, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 451.65M shares, increasing 1.51% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 53.86M shares of this stock.

The company's current financial score is 7.58, which is higher than the Pharmaceuticals industry's average of 6.80. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 8.15B, representing a year-over-year increase of 9.43%, while its net profit experienced a year-over-year increase of 1630.97%.

Score

Industry at a Glance

Previous score

7.58

Change

0



Financials

8.19

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.14

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

7.51

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.51

Key Metrics

Free cash flow

No Data

The company’s current valuation score is 4.80, which is higher than the Pharmaceuticals industry's average of 1.64. Its current P/E ratio is 23.38, which is 51.71% below the recent high of 35.47 and 15.36% above the recent low of 19.79.

Score

Industry at a Glance

Previous score

5.32

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/176

No Data

The company’s current earnings forecast score is 7.03, which is lower than the Pharmaceuticals industry's average of 7.96. The average price target for Amgen Inc is 315.50, with a high of 405.00 and a low of 180.00.

Score

Industry at a Glance

Previous score

7.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 6.92, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 300.07 and the support level at 278.76, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.67

Change

-0.16

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated：2025-09-12

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 6.02. The latest institutional shareholding proportion is 83.89%, representing a quarter-over-quarter decrease of 0.52%. The largest institutional shareholder is The Vanguard, holding a total of 53.47M shares, representing 9.93% of shares outstanding, with 1.61% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

52.63M

+0.28%

State Street Global Advisors (US)

29.18M

-0.86%

BlackRock Institutional Trust Company, N.A.

28.50M

-1.01%

Capital International Investors

15.13M

+23.93%

Capital World Investors

16.70M

+157.12%

Geode Capital Management, L.L.C.

12.73M

+2.02%

Charles Schwab Investment Management, Inc.

12.21M

-7.57%

Invesco Capital Management (QQQ Trust)

11.11M

-0.30%

PRIMECAP Management Company

Star Investors

12.39M

-4.72%

Morgan Stanley Smith Barney LLC

8.73M

+4.21%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a minor effect on the Pharmaceuticals mixed industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The company’s current risk assessment score is 5.78, which is higher than the Pharmaceuticals industry's average of 3.51. The company's beta value is 0.48. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Amgen Inc

AMGN

6.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Royalty Pharma PLC

RPRX

7.69 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Neurocrine Biosciences Inc

NBIX

7.55 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

United Therapeutics Corp

UTHR

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Kiniksa Pharmaceuticals International PLC

KNSA

7.31 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Cardinal Health Inc

CAH

7.28 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

The Stock Score data is powered by TradingKey and updated daily. Rating data is sourced from LESG. Please use the data with caution for reference purposes only.